ERBB2 and neoplasm: Anti-HER2 monoclonal antibodies (e.g., trastuzumab) partly rely on immune-mediated mechanisms and tumor accessibility; CLDN8-high tumors, being more “solid” and less infiltrated, may respond suboptimally.